In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as skin, lung, or bone and soft tissue cancer (sarcomas), they have not yet proven themselves as a treatment method. Tumor shrinkage was achieved only in rare cases, but the side effects were more severe. An international research group led by scientists from the National Center for Tumor Diseases (NCT/UCC) in Dresden has now succeeded for the first time in a phase 1 clinical trial in testing a novel cell therapy approach that also shows promise for solid tumors. The results were now published in the journal Nature Medicine.
In a phase 1 trial involving 40 patients, the research group investigated the use of T cell receptor (TCR)-engineered T cells.
Using genetic engineering techniques, the researchers incorporated a kind of target identification into the T cells to enable them to recognize tumor-specific proteins.
The newly tested IMA203 therapy targets the PRAME peptide, which is produced almost exclusively by tumors and not by healthy tissue.
This enables the T cells to attack tumor cells in a targeted manner without damaging normal cells.
Know more: https://www.sciencedaily.com/releases/2025/04/2504...

• Tags:
• News